High mobility group box 1 mRNA (HMGB1 mRNA)

High mobility group box 1 (HMGB1) mRNA is the transcript responsible for the synthesis of the HMGB1 protein, a highly conserved nuclear protein that functions as a DNA chaperone and a potent Damage-Associated Molecular Pattern (DAMP). While the encoded protein is essential for chromatin stability and transcriptional regulation within the nucleus, its extracellular release during cell injury or active secretion by immune cells triggers robust inflammatory signaling through receptors such as RAGE and TLR4 (Source: PubMed, PMID: 30271551). Targeting the HMGB1 mRNA transcript using RNA interference (RNAi) or antisense oligonucleotides (ASOs) is an emerging therapeutic strategy designed to reduce the overall cellular reservoir of HMGB1, thereby preventing its pathological accumulation and secretion in chronic inflammatory diseases and oncology (Source: PubMed, PMID: 25600488). This approach has shown promise in preclinical models of sepsis, rheumatoid arthritis, and various solid tumors where HMGB1 overexpression correlates with poor prognosis and therapy resistance (Source: UniProt, P09429). By silencing the mRNA, researchers aim to achieve a more sustained reduction in protein activity compared to traditional protein-binding inhibitors.

Other names

HMG1 mRNAAmphoterin mRNAHigh mobility group protein B1 mRNAHMG-1 mRNA

RNA interference (RNAi) leading to mRNA degradation or antisense-mediated RNase H cleavage to prevent the translation of HMGB1 protein.